日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia

吉妥珠单抗奥佐米星 (GO) 加入诱导化疗可消除白血病起始细胞并显著提高急性髓系白血病小鼠模型的生存率

Cathy C Zhang, Zhengming Yan, Bernadette Pascual, Amy Jackson-Fisher, Donghui Stephen Huang, Qing Zong, Mark Elliott, Conglin Fan, Nanni Huser, Joseph Lee, Matthew Sung, Puja Sapra

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia

使用新型抗 CXCR4 IgG1 抗体 (PF-06747143) 靶向 CXCR4 通路治疗慢性淋巴细胞白血病

Manoj K Kashyap, Carlos I Amaya-Chanaga, Deepak Kumar, Brett Simmons, Nanni Huser, Yin Gu, Max Hallin, Kevin Lindquist, Rolla Yafawi, Michael Y Choi, Ale-Ali Amine, Laura Z Rassenti, Cathy Zhang, Shu-Hui Liu, Tod Smeal, Valeria R Fantin, Thomas J Kipps, Flavia Pernasetti, Januario E Castro

Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase

嘌呤核苷酸利用率通过 Rheb GTPase 调节 mTORC1 活性

Natasha Emmanuel, Shoba Ragunathan, Qin Shan, Fang Wang, Andreas Giannakou, Nanni Huser, Guixian Jin, Jeremy Myers, Robert T Abraham, Keziban Unsal-Kacmaz

CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy

CK2 抑制剂 CX-4945 抑制 DNA 靶向抗癌药物引发的 DNA 修复反应并增强疗效:药物联合治疗的机制原理

Adam Siddiqui-Jain, Joshua Bliesath, Diwata Macalino, Mayuko Omori, Nanni Huser, Nicole Streiner, Caroline B Ho, Kenna Anderes, Chris Proffitt, Sean E O'Brien, John K C Lim, Daniel D Von Hoff, David M Ryckman, William G Rice, Denis Drygin